Arrowhead Pharmaceuticals (ARWR) News Today $19.90 -1.06 (-5.06%) Closing price 04:00 PM EasternExtended Trading$19.91 +0.01 (+0.05%) As of 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Arrowhead Pharmaceuticals (ARWR): Among the Most Oversold Healthcare Stocks to Buy NowFebruary 20 at 1:18 PM | insidermonkey.comArrowhead Pharmaceuticals (ARWR): Among the Most Oversold Healthcare Stocks to Buy NowFebruary 20 at 1:17 PM | msn.comArrowhead Pharmaceuticals: Progress During Adverse Market ConditionsFebruary 19 at 12:02 PM | seekingalpha.comFat, not muscle: drugmakers in race for next weight-loss breakthroughFebruary 19 at 6:48 AM | reuters.comB. Riley Has Positive Outlook for ARWR FY2025 EarningsFebruary 18 at 2:39 AM | americanbankingnews.comWhat is HC Wainwright's Estimate for ARWR Q2 Earnings?February 17, 2025 | americanbankingnews.comEquities Analysts Offer Predictions for ARWR FY2025 EarningsArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) - Equities researchers at B. Riley increased their FY2025 earnings per share estimates for shares of Arrowhead Pharmaceuticals in a research report issued on Thursday, February 13th. B. Riley analyst M. Mamtani now anticipates that the bFebruary 17, 2025 | marketbeat.comQ2 Earnings Estimate for ARWR Issued By HC WainwrightArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) - Equities researchers at HC Wainwright issued their Q2 2025 EPS estimates for shares of Arrowhead Pharmaceuticals in a research report issued on Wednesday, February 12th. HC Wainwright analyst P. Trucchio anticipates that the biotechnolFebruary 17, 2025 | marketbeat.comArrowhead Pharmaceuticals' (ARWR) "Buy" Rating Reiterated at B. RileyFebruary 17, 2025 | americanbankingnews.comZacks Small Cap Issues Negative Forecast for ARWR EarningsFebruary 16, 2025 | americanbankingnews.comB. Riley Reiterates "Buy" Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR)B. Riley reissued a "buy" rating and issued a $38.00 price target (down previously from $51.00) on shares of Arrowhead Pharmaceuticals in a report on Friday.February 15, 2025 | marketbeat.comZacks Small Cap Issues Negative Estimate for ARWR EarningsArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) - Equities research analysts at Zacks Small Cap reduced their Q2 2025 earnings estimates for shares of Arrowhead Pharmaceuticals in a research note issued to investors on Wednesday, February 12th. Zacks Small Cap analyst D. Bautz now forFebruary 15, 2025 | marketbeat.comArrowhead Pharmaceuticals' (ARWR) "Buy" Rating Reiterated at HC WainwrightFebruary 15, 2025 | americanbankingnews.comArrowhead price target lowered to $38 from $51 at B. RileyFebruary 14, 2025 | markets.businessinsider.comB.Riley Financial Sticks to Their Buy Rating for Arrowhead Pharmaceuticals (ARWR)February 14, 2025 | markets.businessinsider.comLeerink Partnrs Issues Optimistic Outlook for ARWR EarningsFebruary 14, 2025 | americanbankingnews.comLeerink Partnrs Brokers Raise Earnings Estimates for ARWRArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) - Research analysts at Leerink Partnrs lifted their Q2 2025 earnings estimates for Arrowhead Pharmaceuticals in a research report issued on Tuesday, February 11th. Leerink Partnrs analyst M. Foroohar now forecasts that the biotechnologyFebruary 13, 2025 | marketbeat.comArrowhead Pharmaceuticals' (ARWR) Buy Rating Reiterated at HC WainwrightHC Wainwright reissued a "buy" rating and set a $80.00 target price on shares of Arrowhead Pharmaceuticals in a report on Wednesday.February 13, 2025 | marketbeat.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Edwards Lifesciences (EW), Arrowhead Pharmaceuticals (ARWR) and Exelixis (EXEL)February 13, 2025 | markets.businessinsider.comARWR: Multiple Catalysts Ahead in 2025…February 13, 2025 | finance.yahoo.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Gap Down Following Weak EarningsFebruary 13, 2025 | americanbankingnews.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Trading Down 5% - Should You Sell?Arrowhead Pharmaceuticals (NASDAQ:ARWR) Trading Down 5% - Should You Sell?February 12, 2025 | marketbeat.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Earns "Outperform" Rating from Royal Bank of CanadaFebruary 12, 2025 | americanbankingnews.comChardan Capital Reaffirms Buy Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR)February 12, 2025 | americanbankingnews.comRoyal Bank of Canada Reiterates Outperform Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR)Royal Bank of Canada restated an "outperform" rating and issued a $42.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Tuesday.February 11, 2025 | marketbeat.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Gap Down After Earnings MissArrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Gap Down After Earnings MissFebruary 11, 2025 | marketbeat.comArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q1 2025 Earnings Call TranscriptFebruary 11, 2025 | msn.comChardan Capital Reiterates Buy Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR)Chardan Capital reaffirmed a "buy" rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Tuesday.February 11, 2025 | marketbeat.comArrowhead Pharmaceuticals Reports Q1 2025 Financial ResultsFebruary 10, 2025 | tipranks.comArrowhead Pharmaceuticals, Inc. (ARWR) Q1 2025 Earnings Call TranscriptFebruary 10, 2025 | seekingalpha.comArrowhead reports Q1 EPS ($1.39), consensus (72c)February 10, 2025 | markets.businessinsider.comEarnings call transcript: Arrowhead Pharma misses Q1 2025 forecastsFebruary 10, 2025 | msn.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Posts Quarterly Earnings Results, Misses Expectations By $0.97 EPSArrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) announced its earnings results on Monday. The biotechnology company reported ($1.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.97).February 10, 2025 | marketbeat.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Announces Earnings ResultsArrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) posted its quarterly earnings data on Monday. The biotechnology company reported ($1.39) EPS for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.97).February 10, 2025 | marketbeat.comArrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter ResultsFebruary 10, 2025 | businesswire.comCautious On Arrowhead Pharmaceuticals' FDA NDA Acceptance Due To Valuation ConcernsFebruary 10, 2025 | seekingalpha.comabrdn plc Grows Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)abrdn plc boosted its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 12.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 450,075 shares of the biotechnology company's stock after purchasing an addiFebruary 9, 2025 | marketbeat.comArrowhead Pharmaceuticals (ARWR) Expected to Announce Earnings on MondayArrowhead Pharmaceuticals (NASDAQ:ARWR) will be releasing earnings after the market closes on Monday, February 10, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=658398)February 8, 2025 | marketbeat.comArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Consensus Recommendation of "Moderate Buy" from AnalystsShares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the ten analysts that are currently covering the stock, Marketbeat reports. Four research analysts have rated the stock with a hold rating and six have issued aFebruary 5, 2025 | marketbeat.comGenelux names Matthew Pulisic as CFO, effective January 30February 4, 2025 | markets.businessinsider.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Down 5.9% - What's Next?Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Down 5.9% - Here's WhyFebruary 3, 2025 | marketbeat.comAdeoye Y. Olukotun Sells 959 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) StockJanuary 28, 2025 | insidertrades.comArrowhead Pharmaceuticals (ARWR) to Release Earnings on TuesdayArrowhead Pharmaceuticals (NASDAQ:ARWR) will be releasing earnings before the market opens on Tuesday, February 4, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=658398)January 28, 2025 | marketbeat.comInsider Selling: Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Director Sells 959 Shares of StockArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) Director Adeoye Y. Olukotun sold 959 shares of Arrowhead Pharmaceuticals stock in a transaction dated Thursday, January 23rd. The shares were sold at an average price of $21.00, for a total transaction of $20,139.00. Following the transaction, the director now directly owns 35,781 shares of the company's stock, valued at $751,401. This represents a 2.61 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.January 27, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for ARWR FY2026 Earnings?Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) - Analysts at HC Wainwright cut their FY2026 earnings estimates for Arrowhead Pharmaceuticals in a research report issued to clients and investors on Thursday, January 23rd. HC Wainwright analyst P. Trucchio now expects that the biotechnJanuary 27, 2025 | marketbeat.comArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Sold by Assenagon Asset Management S.A.Assenagon Asset Management S.A. trimmed its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 81.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 53,013 shares of the biotechnology company'sJanuary 25, 2025 | marketbeat.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Trading Down 4.4% - Time to Sell?Arrowhead Pharmaceuticals (NASDAQ:ARWR) Trading Down 4.4% - Here's What HappenedJanuary 24, 2025 | marketbeat.comLeerink Partnrs Issues Negative Outlook for ARWR EarningsArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) - Analysts at Leerink Partnrs lowered their Q3 2025 earnings per share (EPS) estimates for shares of Arrowhead Pharmaceuticals in a note issued to investors on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now anticipatesJanuary 24, 2025 | marketbeat.comArrowhead Pharmaceuticals' SWOT analysis: stock poised for potential breakthroughJanuary 23, 2025 | msn.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Trading Up 6% - Here's WhyArrowhead Pharmaceuticals (NASDAQ:ARWR) Trading 6% Higher - Still a Buy?January 23, 2025 | marketbeat.com Get Arrowhead Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARWR and its competitors with MarketBeat's FREE daily newsletter. Email Address ARWR Media Mentions By Week ARWR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARWR News Sentiment▼0.350.60▲Average Medical News Sentiment ARWR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARWR Articles This Week▼226▲ARWR Articles Average Week Get Arrowhead Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARWR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Qiagen News Ascendis Pharma A/S News Roivant Sciences News Revolution Medicines News Legend Biotech News BridgeBio Pharma News Axsome Therapeutics News Blueprint Medicines News Telix Pharmaceuticals Limited American Depositary Shares News Elanco Animal Health News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ARWR) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arrowhead Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arrowhead Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARWR Stock Alerts